PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.14
D/E ratio at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.16. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
-11.34
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 0.88. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-16.67
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.91
Current ratio 75-90% of Drug Manufacturers - Specialty & Generic median of 2.16. John Neff would demand higher margins to compensate for tighter liquidity.
70.08%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.85%. Michael Burry would check for aggressive accounting and hidden risks.